由于短期低剂量费纳斯特治疗雄激素性脱发症而导致的持续性妇产
Hal Steven Farkas1, Youn Hee Jee2, Vivian Szymczuk3
1College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL 33328, USA.
JCEM case reports
|April 25, 2024
概括
低剂量费纳斯特可以导致男性的持续性妇产不全 (男性乳腺扩大),即使在药物停止后. 早期干预至关重要,以防止乳腺组织不可逆转的变化,并向患者告知这种潜在的副作用.
科学领域:
- 内分泌学 在内分泌学.
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 费纳斯特是一种5α-减少酶抑制剂,通常用于治疗雄激素性脱发症.
- 妇产不良是因其作用机制而已知的费纳斯特的潜在副作用.
- 有限的报告存在于低剂量费纳斯特诱导的妇,这表明报告不足.
研究的目的:
- 报告一个年轻人使用低剂量费纳斯特的持续性妇科的病例.
- 为了突出菲纳斯特可能产生的未被报道的副作用.
- 强调患者咨询和早期干预对于费纳斯特诱导的妇产的重要性.
主要方法:
- 一个20岁的男性患者的病例报告,他经历了持续性妇产不适.
- 停止使用费纳斯特并随后监测妇产不适.
- 使用拉洛西芬 (一种选择性雌激素受体调节剂) 的治疗.
- 对于持久的乳腺组织进行外科干预 (双边乳房整形术).
主要成果:
- 一个健康的20岁男子经过1个月的低剂量费纳斯特后,发生了持续性妇产.
- 在终止使用费纳斯特后的5个月内,妇产不适症保持不变.
- 在拉洛西芬治疗6个月后,观察到妇产不良症的部分回归.
- 一年后,需要手术切除剩余的乳腺组织.
结论:
- 低剂量费纳斯特可能会导致持久且潜在的不可逆转的妇产不良.
- 费纳斯特诱导的妇产的发病率可能显著低于报告.
- 医生应该就这种风险向患者提供建议,并考虑早期干预,以防止纤维化变化.
相关概念视频
Menopause
156
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
156
Disorders of the Male Reproductive System
400
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
400
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
148
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
148
Signs of Puberty
334
Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
334
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
169
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
169
Adrenal Gland Disorders
1.5K
Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
1.5K


